Biodesix Charts Aggressive Growth Path With $106M-$112M 2026 Target Biodesix reported impressive fourth-quarter results demonstrating substantial momentum in its diagnostic testing business. The company achieved 41 percent revenue growth during Q4 2025, significantly outpacing broader market trends and validating its commercial expansion strategy. More notably, Biodesix achieved its first positive EBITDA milestone, a critical inflection point indicating the company has reached operational profitability on an adjusted basis. Management provided forward guidance targeting $106 million to $112 million in 2026 revenue, representing continued double-digit growth expectations. This projection reflects confidence in expanding market adoption of its diagnostic platforms across oncology and other therapeutic areas.
Post from MarketNews_en
Log in to interact with content.